Landos Prices $ 100 Million IPO RTW Venture Fund Limited (the Company ), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by its portfolio company Landos Biopharma, Inc. ( Landos ) on 03 February 2021 of its pricing of a $ 100 million initial public offering ( IPO ) and admission to trade on Nasdaq Global Market under ticker LABP . Landos is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oral therapeutics for patients with autoimmune diseases. The lead asset BT-11 is a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn s disease that targets the LANCL2 pathway.
RTW Participates in $75 Million Financing Round in Immunocore
RTW Venture Fund Limited (the Company ), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by its portfolio company Immunocore, Ltd ( Immunocore ) on 11 January 2021 of its completion of a $75 million Series C financing round. The announcement of the financing round comes following positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma that Immunocore presented in December 2020.
The Company, alongside other investment vehicles of RTW Investments, LP (the Investment Manager ), confirms that it participated in the financing round together with other investment firms.
RTW Participates in $56 Million Financing Round in Biomea Fusion
RTW Venture Fund Limited (the Company ), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Biomea Fusion, Inc. ( Biomea ) on 06 January 2021 of its completion of a $56 million Series A financing round.
The Company, alongside other investment vehicles of RTW Investments, LP (the Investment Manager ), confirms that it participated in the financing round together with other investment firms.
Biomea is a US-based privately held precision oncology company dedicated to developing innovative medicines targeting specific cancer driving mutations. Biomea plans to use the proceeds from the financing round to advance the development of its portfolio of irreversible inhibitors, including a potentially first-in-class irreversible inhibitor of menin, a key newly recognized onco-target